Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on the Effectiveness of NANOULCOR for Patients with Severe Corneal Ulcers Using Allogenic Limbal Cells and Keratocytes

Investigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as corneal ulcer, which is a painful open sore on the clear front surface of the eye. The trial is testing a new treatment called NANOULCOR, which is an artificial cornea made from a special combination of cells. These cells include allogenic sclerocorneal limbus stem-derived adult limbal cells and allogenic corneal-derived adult keratocytes, both of which are expanded outside the body and then combined in a biological matrix to form a living tissue equivalent. This treatment is designed to help patients with severe corneal ulcers that do not respond to standard therapies.

The purpose of the study is to evaluate how well NANOULCOR works in healing the corneal ulcers compared to a control group. Participants in the study will receive the treatment through implantation, and the study will monitor the healing process of the corneal ulcers over time. The trial will also look at other factors such as changes in vision, any complications that may arise, and the overall quality of life of the participants. The study will record any side effects and assess the condition of the implanted corneal construct to ensure it remains intact and does not detach or dissolve.

This trial is a Phase IIb study, which means it is in the middle stages of testing the treatment's effectiveness and safety. It is a randomized, controlled, and unblinded study, meaning participants will be randomly assigned to receive either the new treatment or a control, and both the researchers and participants will know which treatment is being administered. The study is being conducted at multiple centers and aims to provide valuable information on the potential benefits of NANOULCOR for patients with severe corneal ulcers.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and current condition to ensure the presence of severe corneal ulcers that have not responded to conventional treatments.

    A pregnancy test is required for patients of childbearing age, and informed consent must be provided.

  2. Step 2

    Treatment preparation

    Preparation for the treatment involves scheduling the implantation procedure. The treatment uses a product called alogic sclerocorneal limbus stem adult limbal cells combined with alogic corneal differentiated adult keratocytes in a biological matrix.

    This product is a living tissue equivalent and is administered through implantation.

  3. Step 3

    Implantation procedure

    The implantation procedure is performed to introduce the artificial cornea model, known as NANOULCOR, into the affected eye. This procedure aims to regenerate the corneal tissue and address the trophic defect.

  4. Step 4

    Post-implantation monitoring

    Following the implantation, regular follow-up visits are scheduled to monitor the status of the corneal construct. These visits assess the integrity of the implant and check for any detachment or resorption.

    The effectiveness of the treatment is evaluated by observing the healing process, changes in visual acuity, and any corneal complications.

  5. Step 5

    Long-term follow-up

    The study includes a six-month follow-up period to ensure the continued effectiveness and safety of the treatment. During this time, patients are required to use safe methods of birth control if applicable.

    The primary goal is to determine the capacity of NANOULCOR to regenerate the corneal defect compared to a control group.

Who can join the trial?

9 criteria

  • Patients must agree to participate in the study by giving their informed consent.
  • Patients must have trophic corneal ulcers that do not respond to usual medical treatments. These ulcers are caused by specific conditions.
  • Patients who have had this type of corneal ulcer before and now have lasting effects like corneal thinning (thinning of the clear front part of the eye), corneal clouding (cloudiness in the clear front part of the eye), or calcium keratopathy (calcium deposits in the eye).
  • The ulcer may affect the stroma, which is a layer of the cornea, but it should not reach Descemet's membrane, a deeper layer. The ulcer can be located in the center or on the edges of the cornea.
  • Patients must be over 18 years old, with no upper age limit.
  • The disease causing the corneal ulcer must have lasted for at least 3 weeks.
  • Women of childbearing age must have a negative pregnancy blood test.
  • Both men and women of childbearing age must agree to use safe birth control methods during the study and for six months after.
  • Patients must be willing and able to follow the visit schedule, treatment plan, clinical tests, and all study procedures.

Who cannot join the trial?

8 criteria

  • Patients who have any other eye condition that could interfere with the study results.
  • Patients who are currently using any medication that might affect the healing of the eye.
  • Patients who have had eye surgery in the last 3 months.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a known allergy to any of the ingredients in the study medication.
  • Patients who are participating in another clinical trial at the same time.
  • Patients who have a serious illness that could affect their ability to participate in the study.
  • Patients who are unable to follow the study procedures or attend the required visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

NANOULCOR is a nanostructured fibrin-agarose artificial cornea model being tested for its effectiveness in treating patients with severe corneal ulcers. This therapy aims to help regenerate the damaged area of the cornea, potentially improving vision and healing the ulcer.

What is already known about the treatment

NANOULCOR – This medication is administered as an artificial cornea model, applied directly to the eye to treat severe corneal ulcers. It is currently being evaluated in a Phase IIb clinical trial to assess its effectiveness in promoting the regeneration of damaged corneal tissue. The main therapeutic indication for NANOULCOR is the treatment of severe corneal ulcers. At the molecular level, it works by providing a scaffold that supports cell growth and tissue regeneration, utilizing a nanostructured fibrin-agarose matrix. It is classified pharmacologically as a tissue-engineered product designed for ocular surface reconstruction.

Investigated diseases

Corneal Ulcer – A corneal ulcer is an open sore on the cornea, the clear front surface of the eye. It often results from infections, injuries, or wearing contact lenses for extended periods. The condition can cause redness, pain, tearing, and blurred vision. As the ulcer progresses, it may lead to a white or gray spot on the cornea. If untreated, it can result in scarring or vision loss. The healing process involves the regeneration of the corneal tissue, which can vary in duration depending on the severity of the ulcer.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-506856-25-00Protocol codeFIB-NAN-2023-01Estimated enrolment30 patientsSponsorFundacion Publica Para La Investigacion Biosanitaria De Andalucia Oriental Alejandro Otero

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).